The HYPORT Adjuvant trial provides reassuring evidence that regional nodal irradiation delivered with an ultrahypofractionated schedule of 26 Gy in five fractions does not worsen patient-reported quality of life compared with the standard schedule of 40 Gy in 15 fractions.
This multicenter, randomized, noninferiority trial included 2,173 evaluable patients, of whom 1,508 received regional nodal irradiation. Quality of life was assessed using the EORTC QLQ-C30 and FACT-B questionnaires at baseline, at the end of radiotherapy, and at 6, 12, and 18 months after treatment.
Why This Study Matters
One-week breast radiotherapy has already shown important advantages in treatment convenience and healthcare resource use. However, most early evidence came from patients receiving breast-only radiotherapy, while uncertainty remained for those with higher-risk disease who also required nodal treatment.
Regional nodal irradiation may increase exposure of the arm, shoulder, lung, heart, and lymphatic structures. This has raised concerns about lymphedema, arm discomfort, fatigue, pain, dyspnea, and overall quality of life.
The HYPORT Adjuvant trial was designed to test a more pragmatic approach in a broader population, including patients treated after breast-conserving surgery or mastectomy and those receiving regional nodal irradiation.
Trial Design
Patients were randomized to either 40 Gy in 15 fractions over three weeks or 26 Gy in five fractions over one week.
The median age was 52 years in both groups. Regional nodal irradiation was delivered to 69.4% of the study population, most commonly to the supraclavicular region. A smaller group also received internal mammary or axillary irradiation.
The main quality-of-life outcome was global health status, with additional analyses of physical, emotional, social, role, and cognitive functioning, as well as fatigue, pain, dyspnea, breast-specific symptoms, and arm swelling or tenderness.
Main Findings
There was no significant interaction between regional nodal irradiation and fractionation schedule for global quality of life.
At 18 months, the estimated global quality-of-life score among patients receiving nodal irradiation was 71.75 in the 15-fraction group and 71.80 in the five-fraction group. The difference was neither statistically significant nor clinically meaningful.
Quality-of-life scores showed a similar pattern in both groups. They declined initially after treatment and then improved during follow-up.
No significant differences were found in physical, role, emotional, social, or cognitive functioning. Fatigue, pain, dyspnea, FACT-B scores, and breast-specific outcomes were also comparable between the two treatment schedules.
Arm Swelling and Tenderness
At 18 months, moderate or severe arm swelling and tenderness were reported by 7.6% of patients receiving nodal irradiation in the 15-fraction arm and 5.7% in the five-fraction arm.
These findings did not suggest increased arm morbidity with ultrahypofractionated treatment.
Strengths and Limitations
A major strength of the study is its large, multicenter population, with a substantial proportion of patients receiving regional nodal irradiation. This makes the findings highly relevant to routine breast cancer practice.
However, questionnaire completion declined over time, with fewer than half of patients receiving nodal irradiation completing quality-of-life assessments at 18 months. The investigators performed sensitivity analyses, and the main conclusions remained stable unless substantial penalties were applied to missing data.
The analysis was also not prespecified in the original protocol, and follow-up was limited to 18 months. Longer-term data are still needed to evaluate late lymphedema, shoulder dysfunction, pulmonary toxicity, and cardiac effects.
The parent trial’s primary locoregional control results are also still awaited.
Clinical Takeaway
The HYPORT Adjuvant trial shows that regional nodal irradiation delivered as 26 Gy in five fractions over one week does not appear to worsen patient-reported quality of life compared with 40 Gy in 15 fractions over three weeks.
Global quality of life, functional outcomes, symptom burden, and arm swelling or tenderness were similar between the two schedules.
These results strengthen the evidence that one-week radiotherapy may be feasible not only for breast-only treatment, but also for selected patients requiring regional nodal irradiation.
Longer follow-up and final disease-control results will be important before the regimen is fully established as a standard option for higher-risk breast cancer.
Read full article here.